Overview Dividends

(XNCR) Xencor - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98401F1057

Monoclonal Antibodies, Cancer Treatments, Autoimmune Therapies

XNCR EPS (Earnings per Share)

EPS (Earnings per Share) of XNCR over the last years for every Quarter: "2020-09-30": -0.22, "2020-12-31": -0.24, "2021-03-31": -0.04, "2021-06-30": 0.87, "2021-09-30": -0.69, "2021-12-31": 1.21, "2022-03-31": 0.39, "2022-06-30": -0.57, "2022-09-30": -0.55, "2022-12-31": -0.2, "2023-03-31": -1.02, "2023-06-30": -0.37, "2023-09-30": -0.4, "2023-12-31": -0.31, "2024-03-31": -1.11, "2024-06-30": -1.07, "2024-09-30": -0.71, "2024-12-31": -0.62, "2025-03-31": -0.66, "2025-06-30": -0.41,
EPS Growth (3Y CAGR): 8.45%
EPS Trend (3Y Correlation): -19.8%

XNCR Revenue

Revenue of XNCR over the last years for every Quarter: 2020-09-30: 35.366, 2020-12-31: 41.854, 2021-03-31: 33.965, 2021-06-30: 67.447, 2021-09-30: 19.683, 2021-12-31: 154.016, 2022-03-31: 85.495, 2022-06-30: 30.175, 2022-09-30: 27.299, 2022-12-31: 21.61, 2023-03-31: 18.962, 2023-06-30: 45.523, 2023-09-30: 59.164, 2023-12-31: 44.689, 2024-03-31: 12.805, 2024-06-30: 16.96, 2024-09-30: 17.796, 2024-12-31: 70.018, 2025-03-31: 32.732, 2025-06-30: 43.608,
Revenue Growth (3Y CAGR): 18.57%
Revenue Trend (3Y Correlation): 19.2%

Description: XNCR Xencor

Xencor Inc (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company that focuses on developing innovative monoclonal antibodies for various therapeutic areas, including asthma, autoimmune diseases, and cancer. The company has a diverse pipeline of products, including Ultomiris, Monjuvi, and Sotrovimab, which are already being used to treat various conditions. Xencors product portfolio is complemented by a robust research and development pipeline, featuring multiple bispecific antibodies and other novel therapeutics targeting a range of diseases, including cancer, autoimmune disorders, and infectious diseases.

The companys expertise in engineering monoclonal antibodies has enabled it to develop a range of promising candidates, including XmAb819, XmAb541, and XmAb808, which are being evaluated in various stages of clinical trials. Additionally, Xencor has partnered with other pharmaceutical companies, such as Novartis and Janssen, to develop and commercialize its antibody technologies. With a strong presence in the biotechnology industry and a growing pipeline of innovative products, Xencor is well-positioned to capitalize on emerging trends and opportunities in the market.

Analyzing the , we can see that XNCRs stock price has been trending downward, with a current price of $8.40 and a 52-week low of $7.52. The stocks moving averages (SMA20: $8.83, SMA50: $9.06) indicate a potential support level around $8-9. However, the long-term trend (SMA200: $16.66) suggests that the stock is still in a downtrend. The Average True Range (ATR: 0.51 = 6.12%) indicates moderate volatility. Based on this analysis, we can forecast that XNCRs stock price may experience a short-term bounce, potentially reaching $9-10, but the long-term downtrend may continue unless there are significant positive developments in the companys pipeline or partnerships.

From a fundamental perspective, Xencors indicates a market capitalization of $594.99M USD, with a negative P/E ratio and a Return on Equity (RoE) of -32.70%. This suggests that the company is still in a growth phase and has not yet achieved profitability. However, the companys diverse pipeline and partnerships with other pharmaceutical companies may provide opportunities for future growth. Based on this analysis, we can forecast that XNCRs stock price may be influenced by news and developments related to its pipeline products, partnerships, and financial performance. A potential catalyst for the stock price could be positive results from ongoing clinical trials or new partnerships and collaborations.

XNCR Stock Overview

Market Cap in USD 594m
Sub-Industry Biotechnology
IPO / Inception 2013-12-03

XNCR Stock Ratings

Growth Rating -88.9%
Fundamental 26.4%
Dividend Rating -
Return 12m vs S&P 500 -66.2%
Analyst Rating 4.50 of 5

XNCR Dividends

Currently no dividends paid

XNCR Growth Ratios

Growth Correlation 3m -26.8%
Growth Correlation 12m -87.5%
Growth Correlation 5y -91.9%
CAGR 5y -32.74%
CAGR/Max DD 3y -0.40
CAGR/Mean DD 3y -0.77
Sharpe Ratio 12m -1.61
Alpha -77.79
Beta 0.835
Volatility 46.49%
Current Volume 948.2k
Average Volume 20d 778.8k
Stop Loss 8 (-5.8%)
Signal 0.17

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-177.9m TTM) > 0 and > 6% of Revenue (6% = 9.85m TTM)
FCFTA -0.24 (>2.0%) and ΔFCFTA -26.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 254.1% (prev 355.0%; Δ -101.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.15 (>3.0%) and CFO -134.2m > Net Income -177.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 5.34 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (74.3m) change vs 12m ago 20.43% (target <= -2.0% for YES)
Gross Margin 96.31% (prev 90.70%; Δ 5.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 19.25% (prev 16.17%; Δ 3.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2.45 (EBITDA TTM -115.2m / Interest Expense TTM 51.6m) >= 6 (WARN >= 3)

Altman Z'' -3.96

(A) 0.47 = (Total Current Assets 513.1m - Total Current Liabilities 96.1m) / Total Assets 879.4m
(B) -0.89 = Retained Earnings (Balance) -783.3m / Total Assets 879.4m
(C) -0.15 = EBIT TTM -126.6m / Avg Total Assets 852.8m
(D) -3.02 = Book Value of Equity -782.3m / Total Liabilities 259.1m
Total Rating: -3.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 26.41

1. Piotroski 1.0pt = -4.0
2. FCF Yield -65.78% = -5.0
3. FCF Margin data missing
4. Debt/Equity 0.27 = 2.46
5. Debt/Ebitda -1.44 = -2.50
6. ROIC - WACC -25.77% = -12.50
7. RoE -26.73% = -2.50
8. Rev. Trend 19.17% = 1.44
9. EPS Trend -19.83% = -0.99

What is the price of XNCR shares?

As of September 16, 2025, the stock is trading at USD 8.49 with a total of 948,153 shares traded.
Over the past week, the price has changed by +0.95%, over one month by +10.55%, over three months by -6.19% and over the past year by -59.86%.

Is Xencor a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Xencor (NASDAQ:XNCR) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 26.41 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XNCR is around 5.06 USD . This means that XNCR is currently overvalued and has a potential downside of -40.4%.

Is XNCR a buy, sell or hold?

Xencor has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XNCR.
  • Strong Buy: 8
  • Buy: 3
  • Hold: 0
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the XNCR price?

Issuer Target Up/Down from current
Wallstreet Target Price 24.1 183.9%
Analysts Target Price 24.1 183.9%
ValueRay Target Price 5.6 -33.8%

Last update: 2025-09-04 04:52

XNCR Fundamental Data Overview

Market Cap USD = 594.1m (594.1m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 443.9m USD (Cash And Short Term Investments, last quarter)
P/S = 4.0436
P/B = 0.983
Beta = 0.891
Revenue TTM = 164.2m USD
EBIT TTM = -126.6m USD
EBITDA TTM = -115.2m USD
Long Term Debt = 163.0m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.38m USD (from shortTermDebt, last quarter)
Debt = 166.4m USD (Calculated: Short Term 3.38m + Long Term 163.0m)
Net Debt = 23.5m USD (from netDebt column, last quarter)
Enterprise Value = 316.6m USD (594.1m + Debt 166.4m - CCE 443.9m)
Interest Coverage Ratio = -2.45 (Ebit TTM -126.6m / Interest Expense TTM 51.6m)
FCF Yield = -65.78% (FCF TTM -208.3m / Enterprise Value 316.6m)
FCF Margin = -126.9% (FCF TTM -208.3m / Revenue TTM 164.2m)
Net Margin = -108.4% (Net Income TTM -177.9m / Revenue TTM 164.2m)
Gross Margin = 96.31% ((Revenue TTM 164.2m - Cost of Revenue TTM 6.06m) / Revenue TTM)
Tobins Q-Ratio = -0.40 (set to none) (Enterprise Value 316.6m / Book Value Of Equity -782.3m)
Interest Expense / Debt = 4.95% (Interest Expense 8.24m / Debt 166.4m)
Taxrate = 21.0% (US default)
NOPAT = -126.6m (EBIT -126.6m, no tax applied on loss)
Current Ratio = 5.34 (Total Current Assets 513.1m / Total Current Liabilities 96.1m)
Debt / Equity = 0.27 (Debt 166.4m / last Quarter total Stockholder Equity 620.4m)
Debt / EBITDA = -1.44 (Net Debt 23.5m / EBITDA -115.2m)
Debt / FCF = -0.80 (Debt 166.4m / FCF TTM -208.3m)
Total Stockholder Equity = 665.4m (last 4 quarters mean)
RoA = -20.23% (Net Income -177.9m, Total Assets 879.4m )
RoE = -26.73% (Net Income TTM -177.9m / Total Stockholder Equity 665.4m)
RoCE = -15.29% (Ebit -126.6m / (Equity 665.4m + L.T.Debt 163.0m))
RoIC = -17.82% (NOPAT -126.6m / Invested Capital 710.8m)
WACC = 7.96% (E(594.1m)/V(760.5m) * Re(9.09%)) + (D(166.4m)/V(760.5m) * Rd(4.95%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 2.00%
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -208.3m)
EPS Correlation: -19.83 | EPS CAGR: 8.45% | SUE: 1.09 | # QB: True
Revenue Correlation: 19.17 | Revenue CAGR: 18.57%

Additional Sources for XNCR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle